comparemela.com

Latest Breaking News On - Allergan united states inc - Page 4 : comparemela.com

AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

US Continues to Push Demand for Depression Drugs Through 2026 – KSU

Judge Andrews Issues Markman Opinion Construing Five Remaining Terms In Dispute In Six Patents-In-Suit In Hatch-Waxman Action | Fox Rothschild LLP

By Memorandum Opinion entered in Allergan USA, Inc. et al. v. Aurobindo Pharma Ltd., et al., Civil Action No. 19-1727-RGA (D.Del. January 11, 2021), The Honorable Richard G. Andrews construed the five (5) remaining terms in dispute in the six (6) patents-in-suit, U.S. Patent Nos. 8,691,860 (“the ‘860 patent”), 9,115,091 (“the ‘091 patent”), 9,364,489 (“the ‘489 patent”), 9,789,125 (“the ‘125 patent”), 9,675,587 (“the ‘587 patent”) and 10,188,632 (“the ‘632 patent”), in a Hatch-Waxman action concerning Plaintiffs’ VIBERZI® brand (eluxadoline) products for the treatment of irritable bowel syndrome with diarrhea. A complete copy of the

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.